Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Florindo D"'
Autor:
Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, for the Italian Migraine Registry study group
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 611-624 (2024)
Abstract Introduction Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and 3 treatment failures and various comorbidities. Methods A 48-week, prospective, multicenter (n = 26), co
Externí odkaz:
https://doaj.org/article/466e8ed5e5ca4896b88d65d5aed29347
Autor:
Antonio Masiello, Maria Rosa di Cicco, Antonio Spagnuolo, Carmela Vetromile, Giuseppe De Santo, Guido Costanzo, Antonio Marotta, Florindo De Cristofaro, Carmine Lubritto
Publikováno v:
AgriEngineering, Vol 6, Iss 1, Pp 597-619 (2024)
This study focuses on anti-trauma mats designed for buffaloes’ comfort, using as raw materials rubber powder from end-of-life tyres (ELTs) and an isocyanate-based polyurethane resin binder. The first part of the study focused on mat formulation. Wh
Externí odkaz:
https://doaj.org/article/b892dc4ba7c84d87935abb954efcf1df
Autor:
Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d’Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli, for the Italian Migraine Registry study group
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1505-1506 (2024)
Externí odkaz:
https://doaj.org/article/f5602bd6383949dc9350bcf9d3b7efb2
Autor:
Piero Barbanti, Bianca Orlando, Gabriella Egeo, Florindo d’Onofrio, Alberto Doretti, Stefano Messina, Massimo Autunno, Roberta Messina, Massimo Filippi, Giulia Fiorentini, Cristina Rotondi, Stefano Bonassi, Cinzia Aurilia
Publikováno v:
Brain Sciences, Vol 14, Iss 7, p 672 (2024)
We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-fr
Externí odkaz:
https://doaj.org/article/26eb09c512a54deab40567391b3b856f
Autor:
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Paola Torelli, Cinzia Finocchi, Florindo d’Onofrio, Luigi d’Onofrio, Renata Rao, Stefano Messina, Laura Di Clemente, Angelo Ranieri, Massimo Autunno, Giuliano Sette, Bruno Colombo, Antonio Carnevale, Marco Aguggia, Miriam Tasillo, Francesco Zoroddu, Fabio Frediani, Massimo Filippi, Carlo Tomino, Stefania Proietti, Stefano Bonassi, for the FRIEND-Study Group
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic migraine (CM: ≥ 15 days/month), and multiple pr
Externí odkaz:
https://doaj.org/article/b74657ac43e446e0a4584ff5c353b44e
Autor:
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Claudia Altamura, Florindo d’Onofrio, Cinzia Finocchi, Maria Albanese, Marco Aguggia, Renata Rao, Maurizio Zucco, Fabio Frediani, Massimo Filippi, Roberta Messina, Sabina Cevoli, Antonio Carnevale, Giulia Fiorentini, Stefano Messina, Francesco Bono, Paola Torelli, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, for the Italian Migraine Registry study group
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Background and objectives The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% and 100% response at
Externí odkaz:
https://doaj.org/article/a8636b84d9e74446b6075f756a804e03
Autor:
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo FilippiBonassi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, for the FRIEND-Study Group
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials (RCTs). Real-life studies are needed to explore drug effects in uns
Externí odkaz:
https://doaj.org/article/177a4ccbfcd447ef960ecb7c1dbd9556
Autor:
Fabrizio Vernieri, Nicoletta Brunelli, Roberta Messina, Carmelina Maria Costa, Bruno Colombo, Paola Torelli, Simone Quintana, Sabina Cevoli, Valentina Favoni, Florindo d’Onofrio, Gabriella Egeo, Renata Rao, Massimo Filippi, Piero Barbanti, Claudia Altamura
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This stud
Externí odkaz:
https://doaj.org/article/1f427bf9daa3489785fbd6f0a45ce0bd
Autor:
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Giulia Pierangeli, Carlo Lovati, Marco Aguggia, Florindo d’Onofrio, Alberto Doretti, Paola Di Fiore, Cinzia Finocchi, Renata Rao, Francesco Bono, Angelo Ranieri, Maria Albanese, Sabina Cevoli, Piero Barbanti, for the GARLIT Study Group
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galcanezumab in the preve
Externí odkaz:
https://doaj.org/article/e9f68b68492c4c23a77473fa7e851a8d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.